AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...
As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...
National health spending is forecast to approach $9 trillion by 2034, increasing faster than GDP and consuming 20.6% of the ...
Earlier, systematic supportive and palliative integration, plus streamlined logistics and clearer counseling on novel-therapy AE profiles, could reduce household disruption during treatment and ...
CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...
Interrupted time-series signals showed exacerbations increased before 2015 but dropped sharply after 2015 and continued ...
Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...
New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.
Deloitte's Pete Lyons explains the confidence gap, diverging biopharmaceutical and medical technology risks, and what separates real AI value from activity. 259 Prospect Plains Rd, Bldg H Cranbury, NJ ...
Since sickle cell disease trial criteria exclude most patients, Julie Kanter, MD, advocated for broader end points and real-world monitoring to improve inclusion. Current sickle cell disease (SCD) ...
Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results